• TiumBio receives an upfront payment of $4.5 million from Hansoh Pharmaceutical

• Phase 2a clinical trial for TU2670 is ongoing in 5 European countries

September 28, 2022, SEONGNAM, South Korea - TiumBio Co., Ltd.(KOSDAQ: 321550), an R&D-focused clinical-stage biotechnology company based in South Korea, today announced it received an upfront payment of USD 4.5 million from Hansoh Pharmaceutical Group Company Ltd.(SEHK: 3692) for TU2670, a best-in-class GnRH receptor antagonist for the treatment of endometriosis and uterine fibroids.

Last January, TiumBio entered into a licensing agreement and strategic partnership with Hansoh Pharma. TiumBio was entitled to receive upfront and milestone payments of up to USD 170 million including a USD 4.5 million upfront payment and a near-term milestone payment of USD 1.5 million. Under the terms of the agreement, Hansoh obtained an exclusive license from TiumBio to research, develop and commercialize TU2670 in Greater China

 “The partnership between TiumBio and Hansoh Pharma for TU2670 has begun in earnest,” a TiumBio official said. “Apart from the upfront payment received, TiumBio will receive a near-term milestone payment of USD 1.5 million at the completion of technology transfer. We are actively building a collaborative process for successful clinical trials of TU2670 in Greater China.”

Meanwhile, TiumBio is conducting a Phase 2a clinical trial on a total of 80 patients in five European countries. “More than 60% of patients are currently enrolled in this study,” a TiumBio official said. “We plan to complete the study within next year and discuss licensing agreements with global pharmaceutical companies in North America and Europe that have shown great interest in TU2670.

About TU2670

TU2670 is an orally active non-peptide GnRH antagonist under Phase 2a clinical study in the EU for the treatment of endometriosis. The first-in-human (FIH) study of TU2670 with healthy premenopausal female volunteers in South Korea was completed in 2016, demonstrating excellent safety and tolerability of TU2670. The pharmacodynamic measurements from this FIH study indicated the superior suppressive effects of TU2670 on both gonadotropins and sexual hormones at low doses, improving the convenience of administration. (once daily administration) In 2019, the Company signed an exclusive licensing agreement with Deawon Pharma for the development and commercialization of TU2670 in South Korea. Deawon Pharma is currently conducting a Phase 2 clinical trial for the treatment of uterine myoma in South Korea.

About Hansoh Pharmaceutical Group

Hansoh Pharma (3692.HK), one of the largest biopharmaceutical companies in Greater China and Asia, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Founded in 1995, Hansoh Pharma is supported by over 12,150 dedicated employees including over 1,650 highly skilled R&D professionals. The Company has fully integrated research and development, manufacturing, and commercial capabilities, supporting leading positions across a broad range of therapeutic areas, including oncology, Central Nervous System (CNS) disorders, infectious diseases, diabetes, autoimmune diseases and other main therapeutic areas. Hanso Pharma has the second largest number of approved new drugs in China. As of August 2022, the Company’s market capitalization is about 11B, and the Company is an affiliate of Jiangsu Hengrui Medicine, the largest company by market capitalization in China.

Contacts

TiumBio

Suna Cho 

Corporate Planning Team Manager

Email: sunacho@tiumbio.com